Silo Pharma (NASDAQ:SILO – Get Free Report) and Ono Pharmaceutical (OTCMKTS:OPHLF – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.
Volatility and Risk
Silo Pharma has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500. Comparatively, Ono Pharmaceutical has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500.
Profitability
This table compares Silo Pharma and Ono Pharmaceutical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Silo Pharma | -6,726.39% | -81.75% | -66.35% |
| Ono Pharmaceutical | 15.02% | 9.77% | 7.63% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Silo Pharma | 1 | 0 | 0 | 0 | 1.00 |
| Ono Pharmaceutical | 0 | 1 | 0 | 0 | 2.00 |
Valuation & Earnings
This table compares Silo Pharma and Ono Pharmaceutical”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Silo Pharma | $70,000.00 | 40.20 | -$4.23 million | ($4.36) | -0.41 |
| Ono Pharmaceutical | $3.43 billion | 2.21 | $436.04 million | $1.05 | 15.34 |
Ono Pharmaceutical has higher revenue and earnings than Silo Pharma. Silo Pharma is trading at a lower price-to-earnings ratio than Ono Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
5.6% of Silo Pharma shares are owned by institutional investors. 3.6% of Silo Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Ono Pharmaceutical beats Silo Pharma on 8 of the 12 factors compared between the two stocks.
About Silo Pharma
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company’s two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company’s research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
About Ono Pharmaceutical
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.
Receive News & Ratings for Silo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
